Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in a subset of stem-like bladder cancer cells

Fig. 7

Proposed model for the role of LASS2 in cisplatin resistance in bladder cancer. Left: Loss of LASS2 leads to activation of PP2A by increasing C18-ceramide, while PP2A dephosphorylates β-catenin to promote nuclear translocation and activate β-catenin/TCF4 signaling. Right: LASS2 decreases PP2A activity by reducing C18-ceramide and dissociating PP2A from β-catenin, leading to the degradation of phospho-β-catenin

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us